| Name | Title | Contact Details |
|---|
Community Healthcare Network of New York is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Community Healthcare Network of New York is based in New York, NY. You can find more information on Community Healthcare Network of New York at www.chnnyc.org
Mercy and Truth Medical Missions is a non-profit organization that provides healthcare to the underserved people of the Kansas City community and world through Christian service.
Blue Cross Blue Shield of Kansas City (BCBSKC) is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Blue Cross Blue Shield of Kansas City (BCBSKC) is based in Kansas City, MO. You can find more information on Blue Cross Blue Shield of Kansas City (BCBSKC) at www.bcbskc.com
"Gentiva Health Services (NASDAQ: GTIV), formerly based in Melville, Long Island, New York and now in Atlanta, Georgia, is the largest provider of home health care, hospice and related services in the United States. Gentiva is a Fortune 1000 company with $1.7 billion in annual revenue. Gentiva is also a member of the S&P 600 index, developed by Standard & Poor's, featuring small capitalization U.S.-based stocks. The company offers a range of services, including nursing, physical, occupational, and speech-language therapy, cardiac and pulmonary care, disease and pain management, and other health and medical services. Gentiva provides health services to over half a million patients annuallythrough over 380 U.S. locations in 39 states. According to Morningstar, "Gentiva is a gentle giant...the nation's largest home health care services firm." Gentiva companies include Donelson, Emerald Coast, Gilbert's, Healthfield Group, Heritage, Horizon, Hospice of Charleston, Lazarus House, Tar Heel, Total Care and Wiregrass."
Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.